
Earnings Estimates Rising for FormFactor (FORM): Will It Gain?
FormFactor (FORM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
En güncel finans ve ekonomi haberlerini, piyasa gelişmelerini, raporları ve analizleri PipVero’da takip edin.

FormFactor (FORM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

ADTN is expanding its AI networking portfolio, but execution issues and margin pressure may delay the payoff from growing AI infrastructure demand.

RARE beats Q2 earnings estimates as revenues surge year over year to a record quarterly high, driven by higher product sales across its portfolio.

Plexus is delivering faster growth, higher earnings and wider margins, but premium valuation and weaker near-term cash flow temper the buy case.

The Danish company developed the most lucrative new drug the world had ever seen. Then America's Eli Lilly outmaneuvered it and took control of the diet-drug market.

HF Sinclair (DINO) is rated Buy, with 50% upside to a $133 price target, driven by sustained tightness in global refined products markets. DINO's diversified model, including midstream and marketing, buffers refining margin volatility; the upcoming lubricants spinoff provides additional upside potential. Consensus forecasts underestimate the duration of elevated crack spreads, assuming rapid normalization, while my base case expects prolonged high margins due to persistent geopolitical disruptions.

SolarEdge Technologies (NASDAQ:SEDG) shares fell about 24% on Wednesday after the solar technology company issued a weaker-than-expected third quarter outlook, overshadowing better-than-expected second quarter results. The company guided for Q3 2026 revenue of $310 million to $340 million, with a midpoint of $325 million, below analyst expectations of roughly $368 million to $372 million.

Berkshire Hathaway finished selling its Amazon (NASDAQ:AMZN | AMZN Price Prediction) position earlier this year in two clean sweeps.

Income investors have intriguing opportunities and a narrow decision window this week.

Amgen beats Q2 earnings and revenue estimates and lifts its 2026 outlook. Key products witness strong growth despite biosimilar pressure on older drugs.

Marvell Technology's MRVL communications and other business segment has been recovering as customer inventories normalize. In the first quarter of fiscal 2027, communications and other revenues increased 29% year over year to $585 million.

Boston Scientific's cheaper valuation offers upside, but weaker guidance, share losses, higher debt and delayed catalysts favor patience.

J's Q3 revenues top estimates as record backlog and AI-related infrastructure demand support growth, even as the stock fell after results.

KTOS delivers sharp Q2 earnings and revenue growth as government solutions, organic gains and strong bookings support performance.

Lucid's Q2 revenues jump 56.2% and beat estimates, but a $300 million inventory charge widens losses and keeps margins deeply negative.